Details emerge in link between body mass index, chemotherapy response
MD Anderson researchers discussed new data on the connection between body mass index (BMI) and response to presurgical chemotherapy in patients with inflammatory breast cancer during a poster discussion at the 36th annual CTRC-AACR San Antonio Breast Cancer Symposium.
The study examined 1,002 cases of patients with inflammatory breast cancer or locally advanced non-inflammatory breast cancer between 2006-2012. It was the first...
Drug combo helps 95% of CLL clinical trial patients; ibrutinib resistance studied
Even as the targeted therapy ibrutinib makes its way through clinical trials as a single treatment for chronic lymphocytic leukemia (CLL),...
Super gene MUC5B provides mucus required for strong airway defense
In a typical day, each of us swallows 30 milliliters of mucus from our lungs. A mucus blanket is swept from the most distant airways up the...
Researchers call on Sleeping Beauty to arm T cells against cancer #ASH13
When it comes to equipping T cells, the immune system's attack dogs, to find and kill cancer cells, Sleeping Beauty just might be a heroine in the story.
Genetically altering T cells to recognize a surface protein called CD19 and destroy cells that wear it has shown great promise for treating blood cancers, most recently in clinical trials presented during this week at the 55th American Society of Hematology (ASH) Annual Meeting...
New targeted therapy halts CLL for more than 2 years and counting
Patients on an extended clinical trial of the targeted therapy ibrutinib have their relapsed or resistant chronic lymphocytic leukemia stymied...
Institutions team up to form 'collective brain' to defeat lethal brain tumor
Glioblastoma multiforme, the most common and lethal form of brain cancer, "is one of the science and medical world's hardest nuts to crack...
FDA lymphoma drug approval based on MD Anderson-led clinical trial
The U.S. Food and Drug Administration today approved ibrutinib for treatment of patients with mantle cell lymphoma who have received at least...
Advanced form of proton therapy offers benefits for head, neck cancer patients
Oral cancer patients with tumors at the back of the throat are half as likely to require a feeding tube when treated with intensity modulated...
Eating and swallowing exercises during treatment benefit cancer patients later
New MD Anderson research published in JAMA Otolaryngology Head and Neck Surgery indicates that oral exercises help patients maintain their...
Head and neck cancer patients have varied risks for second malignancies
MD Anderson-led research published in the journal Cancer is shedding light on the risk of second primary malignancies, a leading cause of...
Joining a clinical trial to prevent breast cancer recurrence
I finished the most active treatment phase for male breast cancer in the first week of June, enjoyed a few weeks off...
Brain tumor thrives when its immature cells are safe from growing up
In glioblastoma multiforme (GBM), the most common and lethal brain tumor, lack of differentiation makes a big, and bad...
First targeted drug may end cancer-promoting Skp2's days of dodging bullets
A protein called Skp2, overexpressed in many types of cancer, for years has gotten away with promoting tumor growth and progression unhindered...
Triple-negative breast cancer thrives by producing its own growth factors
Triple-negative breast cancer cells produce inflammatory cytokines Interleukin-6 (IL-6) and Interleukin-8 (IL-8), which in turn stimulate...
Research uncovers tie between two cancer-promoters in breast cancer
MD Anderson scientists have found a molecular signaling pathway that connects two known contributors to cancer cell growth and survival. They...
Protein biomarker may signify aggressive colon cancer
MET protein levels correlate strongly with a cellular transition that occurs in a treatment-resistant type of colorectal cancer, according...
Brain cancer: Cognition and quality of life important factors
In a large national, cooperative trial led by MD Anderson, researchers determined bevacizumab (Avastin), did not offer survival benefit to...
Drug doesn't extend survival for newly diagnosed glioblastoma patients
Following surgery, radiation and chemotherapy with a drug that hinders formation of tumor-supporting blood vessels does...
Immunotherapy researcher inspiring hope beyond the lab
Why is our immune system usually not capable of eradicating cancerous tumor cells?
This is the main question that Greg Lizee, Ph.D....
Arrested development: Suffocating cancer cells cheat death with immature miRNA
The epidermal growth factor receptor (EGFR) often goes haywire in cancer, sending constant, urgent signals into a cell, telling it to grow...
Fast food restaurants contribute to African-Americans tipping the scale
The U.S. Centers for Disease Control and Prevention estimates obesity to be a contributing factor to millions of dollars in health care costs...
Key protein fires up central nervous system inflammation
A pivotal protein leads to autoimmune inflammation of the central nervous system in a mouse model of multiple sclerosis (MS) and potentially...
Challenges and opportunities in drug discovery and development
"Cancer is a complex and heterogeneous disease driven by gene mutations. As we enter the era of personalized medicine, the characterization...
MD Anderson cancer research revealed, honored at AACR annual meeting
MD Anderson scientists Jim Allison and Hagop Kantarjian, at left, and Guillermina Lozano and Gabriel Hortobagyi, at right, won four of 14...
MD Anderson genetics chair Guillermina Lozano wins AACR lectureship
The first of six awards to scientists at The University of Texas MD Anderson Cancer Center at this year's AACR Annual Meeting 2013 went to...
Study uncovers actin's action in the nucleus, a break in protein's puzzling case
Actin is a protein that has been long known to work by linking itself into chains to form filaments. Providing rigidity to the cell, actin...
New drugs are too slow getting to children with cancer
Recently, the U.S. Food and Drug Administration (FDA) approved the use of Gleevec in combination with chemotherapy to treat newly diagnosed...
Cancer vaccine ingredient subverts immune attack, diverts it from tumors
For years, scientists have crafted vaccines designed to treat cancer, rather than to prevent it, by priming the immune system to track down...
New approach helps more smokers connect to tobacco treatment
Smoking remains the leading cause of preventable illness and death in the United States, so the health benefits of quitting are substantial...
New initiatives drive personalized cancer care via genetic analysis of tumors
Gordon Mills, M.D., Ph.D., recalls a proposal he wrote 18 years ago detailing the concept of personalized cancer therapy and its potential...
Drug is first to control recurrent low-grade ovarian cancer
A phase 2 clinical trial of a targeted therapy provides evidence that there might, at last, be a treatment that shrinks or stifles the growth...
Killer wound-healing; stress and ovarian cancer; blood vessels' bad signals
A key to the perils of endless injury repair, the molecular path from stress through a cancer-promoting gene to ovarian...
Chromatin gets a makeover; review in Cell explains
Chromatin, the intertwined histone proteins and DNA that are packaged into chromosomes, has long been recognized...
Rescuer has TRAF3's back, keeping cancer and autoimmunity at bay
When a crucial enzyme is dotted with targets that summon an attack by a cell's protein-destroying complex, another molecule comes to the rescue...
Translating research into better treatment: We can boost our batting average
By Naoto Ueno M.D., Ph.D.
Each year, on the basis of new basic research discoveries and clinical observations, my research group generates...
Innovator plans to map genome of single cells to paint cancer's big picture
Cancer begins when a single cell goes haywire. Now the keys to understanding that cell's transition to lethal tumor may be found in the unprecedented...